Bailard’s Iovance Biotherapeutics IOVA Stock Holding History

Bailard’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-130,000	Closed	-$377K	–	511
2019 Q4	$377K	Buy	+130,000	New	+$2.96M	0.02%	369

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bailard's IOVA Position: Q1 2025 in Review

Bailard sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 12,700 shares — an estimated $94K sold.

Bailard first reported a position in IOVA in Q3 2019 and held it in 12 quarters. The position peaked at $4.42M in Q4 2019. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

Bailard reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
Bailard sold 12,700 Iovance Biotherapeutics shares in Q1 2025, an estimated $94K.
Bailard first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 12 quarters.
Bailard's Iovance Biotherapeutics position peaked at $4.42M in Q4 2019.
301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Bailard's 13F filing for Q1 2025, filed 2 May 2025.